PMV Pharmaceuticals, Inc.
PMVPHealthcare|Biotechnology|US
$1.26
-0.01 (-1.18%)
DCF Value
$0.65
Tangible Book / Share
$1.34
Cash / Share
$1.49
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor, Advanced Malignant Neoplasm | P1P2 | Recruiting | 300 | Open-label | rezatapopt, pembrolizumab |
| NCT06616636 A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | Myelodysplastic Syndrome, Acute Myeloid Leukemia | P1 | Recruiting | 24 | Open-label | Azacitidine, Rezatapopt |
| NCT07372625 A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | TP53 Y220C Mutation, Advanced Solid Tumors | P1 | Recruiting | 14 | Open-label | metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt |
| NCT06362642 A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants | Healthy Volunteers | P1 | Completed | 12 | Open-label | PC14586, Itraconazole |
| NCT05249348 Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers | Healthy Volunteers | P1 | Completed | 34 | RCT, Open-label | PC14586 |
| NCT05523687 AME Study of [14C]-PC14586 in Healthy Male Participants | Healthy Male Volunteers | P1 | Completed | 8 | Open-label | [14C]-PC14586 |
| NCT06054464 A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants | Healthy Volunteers | P1 | Completed | 28 | Open-label | PC14586, Rabeprazole, Famotidine |